Gedatolisib for Metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy that lowers testosterone.
Celcuity Inc
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
NCT06190899 on ClinicalTrials.gov →Study type
interventional
Design
Phase 1/2, open-label, randomi…
Target enrollment
54
Est. completion
2028-01
Investor scorecard
Probability of success
moderate
Timeline to catalyst
The trial started in January 2024 and is expected to complete by January 2028. Initial safety data from Phase 1 may be available in 2025, and Phase 2 efficacy data could be available in 2026-2027. Investors should watch for interim analyses and presentations at major oncology conferences (ASCO, ESMO).
Potential stock impact
transformativeThe trial is early-stage (Phase 1/2) with a small sample size (54 patients). The combination is scientifically rational, but the history of PI3K/mTOR inhibitors in prostate cancer has been disappointing. The primary endpoint in Phase 2 is rPFS, which is a surrogate that may not predict overall survival. The competitive landscape is intense, with many approved therapies. However, the trial is well-designed and the sponsor has experience with gedatolisib in other indications. Overall, the probability of success is moderate, perhaps 20-30% for eventual regulatory approval, but for Phase 2 success (meeting rPFS endpoint), it could be higher, around 40-50%.
What is being tested?
This trial tests a new combination of two drugs for men with a specific type of advanced prostate cancer called metastatic castration-resistant prostate cancer (mCRPC). The main drug, gedatolisib, is a targeted therapy that blocks a protein called PI3K/mTOR, which is often overactive in cancer cells and helps them grow. The second drug, darolutamide, is an androgen receptor inhibitor that blocks the effects of male hormones that fuel prostate cancer. The idea is that combining these two drugs might be more effective than either alone, because they attack the cancer through different pathways. The trial is in early stages (Phase 1/2), meaning it's testing safety and dosing first, then looking for signs of effectiveness.
How does the trial work?
The trial is open-label, meaning both patients and doctors know which treatment is given. It is randomized, so patients are assigned to one of several treatment groups by chance. The study has two parts: Phase 1 (dose finding) and Phase 2 (dose expansion). In Phase 1, different doses of gedatolisib are tested in combination with a fixed dose of darolutamide to find the safest and most effective dose (RP2D). In Phase 2, patients are randomized to receive either the combination or possibly a control (though the comparator is not specified, it may be darolutamide alone or another standard). Patients will receive treatment until their cancer progresses or they experience unacceptable side effects. They will have regular imaging scans and blood tests to monitor their cancer and overall health.
What does success look like?
Success in Phase 1 is finding a dose that is safe and tolerable, with manageable side effects. In Phase 2, the main measure of success is radiographic progression-free survival (rPFS), which is the length of time patients live without their cancer growing or spreading on scans. For context, in mCRPC, current treatments like enzalutamide or abiraterone typically extend rPFS by about 4-6 months compared to placebo. A meaningful improvement would be if the combination shows a rPFS that is significantly longer than what is expected from darolutamide alone (which is not yet approved for mCRPC but is being studied). The trial will also look at PSA levels (a prostate cancer marker) and overall survival as secondary measures. If the combination shows a strong signal of activity, it could lead to a larger Phase 3 trial.
What it means for investors
For investors, this trial is an early-stage opportunity with significant risk. Celcuity is a small biotech company, and this trial is a key part of their pipeline. Positive results could be a major catalyst, potentially leading to a significant stock price increase. However, Phase 1/2 trials have a high failure rate, and the timeline is long (expected completion in 2028). If the trial shows safety and promising efficacy, it could attract partnership interest or funding for further development. Conversely, if the trial fails or shows poor tolerability, it could be a major setback. Investors should watch for interim data releases, which could occur at medical conferences or in press releases. The stock impact could be transformative if the combination proves to be a best-in-class therapy for mCRPC, but it's too early to tell. Realistic expectations: the probability of success is moderate, given the early stage and the competitive landscape.
Trial endpoints
Primary endpoints
Secondary endpoints
Competitive landscape
The market for mCRPC treatments is substantial, with global sales of existing therapies exceeding $10 billion annually. The patient population is significant, with thousands of men diagnosed each year. There is a high unmet need for therapies that overcome resistance to current androgen receptor inhibitors. If gedatolisib plus darolutamide can demonstrate improved efficacy and manageable toxicity, it could capture a meaningful share of the market, especially if it can be used earlier in the disease course. However, the competitive landscape is crowded with many approved drugs and numerous investigational agents, so differentiation is key.
| Drug | Sponsor | Phase | Differentiation |
|---|---|---|---|
| Enzalutamide (Xtandi) | Astellas/Pfizer | Phase 1 | Approved for mCRPC, works by blocking androgen receptor signaling. It is a standard of care, but resistance develops. |
| Abiraterone (Zytiga) | Janssen | Phase 1 | Approved for mCRPC, inhibits androgen production. Also a standard of care. |
| Olaparib (Lynparza) | AstraZeneca/Merck | Phase 1 | PARP inhibitor for mCRPC with BRCA mutations. Targets DNA repair defects. |
| Cabazitaxel (Jevtana) | Sanofi | Phase 1 | Chemotherapy used after progression on docetaxel. Not targeted. |
| Radium-223 (Xofigo) | Bayer | Phase 1 | Targeted alpha therapy for bone metastases in mCRPC. |
Historical context
Prior trial results
Gedatolisib has been studied in other solid tumors, including breast cancer, where it has shown activity in combination with other agents. In a Phase 1 trial, gedatolisib was well tolerated with manageable side effects. Darolutamide is already approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and is being studied in mCRPC. The combination of a PI3K/mTOR inhibitor with an androgen receptor inhibitor is a rational approach, as PI3K pathway activation is a known resistance mechanism to androgen receptor therapy.
Regulatory history
Darolutamide is approved for nmCRPC. Gedatolisib has not received any breakthrough or fast track designations for prostate cancer. This trial is in early stages, so no regulatory decisions are pending.
Similar drug precedents
Other PI3K/mTOR inhibitors have been tested in prostate cancer with limited success. For example, everolimus (an mTOR inhibitor) showed modest activity in mCRPC but was not approved. The combination approach with an AR inhibitor is novel and may overcome resistance, but precedent suggests that targeting this pathway alone is not sufficient. However, the combination might be more effective if it addresses resistance mechanisms.